Chen Xiaoyun, Stoneburner Kris, Ladika Mladen, Kuo Tzu-Chi, Kalantar Thomas H
Analytical Sciences, Core R&D, Dow Chemical Company, Midland, MI 48667 USA.
Appl Spectrosc. 2015 Nov;69(11):1271-80. doi: 10.1366/15-07914.
Low aqueous solubility of active pharmaceutical ingredients (APIs) is an enduring problem in pharmaceutical development, and it is becoming increasingly prevalent among new drug candidates. It is estimated that about 40% of drugs in the development pipeline and approximately 60% of the drugs coming directly from discovery suffer from poor aqueous solubility and slow dissolution, thereby reducing their bioavailability and efficacy and thus preventing their commercialization. It is well known that utilizing the amorphous form of a drug can be a useful approach to improve the dissolution rate and solubility of poorly water-soluble APIs. Amorphous compounds are thermodynamically unstable, but they can be stabilized by combining them with a carrier polymer (excipient) to form a solid dispersion. High-throughput Raman spectroscopy was used in this study to identify excipients that promote formation and stabilization of the amorphous drug form in solid dispersions. Four model APIs were used as poorly soluble drug candidates: ketoprofen, danazol, griseofulvin, and probucol. The Raman signals of excipients were generally negligible, and therefore Raman bands from the drugs were used with minimal spectral pre-processing. By comparing Raman spectra collected from the APIs in the crystalline and molten state, appropriate spectral features and regions were identified for the development of semi-quantitative methods to determine the amorphous content for each API. It is demonstrated that methods based on peak intensity ratio, peak width, peak distance, and classical least squares can all be effective methods for the screening of excipients. Interesting excipient-dependent phase transformation behavior was also observed for probucol.
活性药物成分(APIs)的低水溶性是药物研发中一个长期存在的问题,并且在新的候选药物中越来越普遍。据估计,处于研发阶段的药物中约40%以及直接来自发现阶段的药物中约60%都存在水溶性差和溶解缓慢的问题,从而降低了它们的生物利用度和疗效,进而阻碍了它们的商业化。众所周知,利用药物的无定形形式可能是提高难溶性活性药物成分溶解速率和溶解度的一种有用方法。无定形化合物在热力学上是不稳定的,但它们可以通过与载体聚合物(辅料)结合形成固体分散体来实现稳定。本研究使用高通量拉曼光谱来识别促进固体分散体中无定形药物形式形成和稳定的辅料。四种模型活性药物成分被用作难溶性候选药物:酮洛芬、达那唑、灰黄霉素和普罗布考。辅料的拉曼信号通常可以忽略不计,因此来自药物的拉曼谱带在进行最少的光谱预处理后被使用。通过比较从处于结晶态和熔融态的活性药物成分收集的拉曼光谱,确定了合适的光谱特征和区域,用于开发半定量方法来测定每种活性药物成分的无定形含量。结果表明,基于峰强度比、峰宽、峰间距和经典最小二乘法的方法都可以成为筛选辅料的有效方法。还观察到普罗布考存在有趣的辅料依赖性相变行为。